東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

DNA vaccine against HIV-1 Gag: From the bench to the field.

Record Type:	Electronic resources : Monograph/item
Title/Author:	DNA vaccine against HIV-1 Gag: From the bench to the field./
Author:	Qiu, Jian-Tai.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2001,
Description:	167 p.
Notes:	Source: Dissertations Abstracts International, Volume: 63-01, Section: B.
Contained By:	Dissertations Abstracts International63-01B.
Subject:	Microbiology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3006329
ISBN:	9780493156446

DNA vaccine against HIV-1 Gag: From the bench to the field.
Qiu, Jian-Tai.

DNA vaccine against HIV-1 Gag: From the bench to the field. - Ann Arbor : ProQuest Dissertations & Theses, 2001 - 167 p.

Source: Dissertations Abstracts International, Volume: 63-01, Section: B.

Thesis (Ph.D.)--The Johns Hopkins University, 2001.

This item must not be sold to any third party vendors.

We have summarized our efforts over the last several years to enhance the immunogenecity of HIV-1 Gag DNA vaccines. By destroying the inhibitory sequences in the coding region of HIV-1 Gag, we not only significantly increased the protein expression of HIV-1 in various cell types in a Rev-independent fashion, we have also enhanced both T helper and CTL responses in mice immunized with these novel DNA vaccines (Qiu et al., 1999). Subsequently, we have demonstrated that increasing the release of Gag from producer cells after DNA immunization could enhance both T helper and CTL responses (Qiu et al., 2000). We also showed that by targeting the secreted Gag antigen to antigen presentation cells through fusion with ligands of antigen presentation cells such as CTLA-4 (Qiu et al., 2001 submitted), CD40L, and MCP-3, we will be able to further enhance humoral or cellular immune responses. After 4 years of preparatory effort, our group just recently set up China's first HIV/AIDS cohort study based on 700 IV drug users in Guangxi Province. We have received grant support from the NIH to do the clinical trial in Guangxi Province. We are designing and implementing effective intervention/vaccination strategies targeted toward both injection drug use and high risk sexual behavior to reduce HIV-1 spread in China.

ISBN: 9780493156446Subjects--Topical Terms:

536250
Microbiology.
Subjects--Index Terms:

Cellular immune response

DNA vaccine against HIV-1 Gag: From the bench to the field.
LDR:02577nmm a2200397 4500 001 2342270
005 20220311105625.5
008 241004s2001 ||||||||||||||||| ||eng d
020 $a 9780493156446
035 $a (MiAaPQ)AAI3006329
035 $a AAI3006329
040 $a MiAaPQ $c MiAaPQ
100 1 $a Qiu, Jian-Tai. $3 3680606
245 1 0 $a DNA vaccine against HIV-1 Gag: From the bench to the field.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2001
300 $a 167 p.
500 $a Source: Dissertations Abstracts International, Volume: 63-01, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Burke, Donald.
502 $a Thesis (Ph.D.)--The Johns Hopkins University, 2001.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a We have summarized our efforts over the last several years to enhance the immunogenecity of HIV-1 Gag DNA vaccines. By destroying the inhibitory sequences in the coding region of HIV-1 Gag, we not only significantly increased the protein expression of HIV-1 in various cell types in a Rev-independent fashion, we have also enhanced both T helper and CTL responses in mice immunized with these novel DNA vaccines (Qiu et al., 1999). Subsequently, we have demonstrated that increasing the release of Gag from producer cells after DNA immunization could enhance both T helper and CTL responses (Qiu et al., 2000). We also showed that by targeting the secreted Gag antigen to antigen presentation cells through fusion with ligands of antigen presentation cells such as CTLA-4 (Qiu et al., 2001 submitted), CD40L, and MCP-3, we will be able to further enhance humoral or cellular immune responses. After 4 years of preparatory effort, our group just recently set up China's first HIV/AIDS cohort study based on 700 IV drug users in Guangxi Province. We have received grant support from the NIH to do the clinical trial in Guangxi Province. We are designing and implementing effective intervention/vaccination strategies targeted toward both injection drug use and high risk sexual behavior to reduce HIV-1 spread in China.
590 $a School code: 0098.
650 4 $a Microbiology. $3 536250
650 4 $a Immunology. $3 611031
650 4 $a Public health. $3 534748
650 4 $a Deoxyribonucleic acid--DNA. $3 3546879
650 4 $a Vaccines. $3 684854
650 4 $a Human immunodeficiency virus--HIV. $3 3564909
653 $a Cellular immune response
653 $a DNA vaccine
653 $a Gag
653 $a HIV-1
653 $a Immune deficiency
690 $a 0410
690 $a 0982
690 $a 0573
710 2 $a The Johns Hopkins University. $3 1017431
773 0 $t Dissertations Abstracts International $g 63-01B.
790 $a 0098
791 $a Ph.D.
792 $a 2001
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3006329